ribociclib 200 MG Oral Tablet [Kisqali]
- RxCUI
- 1873989
- RxNorm name
- ribociclib 200 MG Oral Tablet [Kisqali]
- Display name
- ribociclib 200 MG Oral Tablet [Kisqali]
- Full name
- ribociclib 200 MG Oral Tablet [Kisqali]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:14
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| KISQALI | RIBOCICLIB | Novartis Pharmaceuticals Corporation | aaeaef94-f3f5-4367-8ea2-b181d7be2da8 | 2026-07-01 | Warnings, Adverse reactions | 1873989 |
| KISQALI FEMARA CO-PACK | LETROZOLE AND RIBOCICLIB | Novartis Pharmaceuticals Corporation | aa5e4446-19cd-4235-a382-5b48bf6c3b2f | 2026-07-01 | Warnings, Adverse reactions | 1873989 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| aaeaef94-f3f5-4367-8ea2-b181d7be2da8 | ribociclib 200 MG Oral Tablet [Kisqali] | SBD | 27 | These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI. KISQALI ® (ribociclib) tablets, for oral use Initial U.S. Approval: 2017 | 20251215 |
| aaeaef94-f3f5-4367-8ea2-b181d7be2da8 | Kisqali 200 MG (equivalent to ribociclib succinate 254.4 MG) Oral Tablet | SY | 27 | These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI. KISQALI ® (ribociclib) tablets, for oral use Initial U.S. Approval: 2017 | 20251215 |
| aaeaef94-f3f5-4367-8ea2-b181d7be2da8 | Kisqali 200 MG Oral Tablet | SY | 27 | These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI. KISQALI ® (ribociclib) tablets, for oral use Initial U.S. Approval: 2017 | 20251215 |
| aaeaef94-f3f5-4367-8ea2-b181d7be2da8 | Kisqali 200 MG Oral Tablet | PSN | 27 | These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI. KISQALI ® (ribociclib) tablets, for oral use Initial U.S. Approval: 2017 | 20251215 |
| aa5e4446-19cd-4235-a382-5b48bf6c3b2f | Kisqali 200 MG (equivalent to ribociclib succinate 254.4 MG) Oral Tablet | SY | 25 | These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI ® FEMARA ® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use Initial U.S. Approval: 2017 | 20250916 |
| aa5e4446-19cd-4235-a382-5b48bf6c3b2f | ribociclib 200 MG Oral Tablet [Kisqali] | SBD | 25 | These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI ® FEMARA ® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use Initial U.S. Approval: 2017 | 20250916 |
| aa5e4446-19cd-4235-a382-5b48bf6c3b2f | Kisqali 200 MG Oral Tablet | SY | 25 | These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI ® FEMARA ® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use Initial U.S. Approval: 2017 | 20250916 |
| aa5e4446-19cd-4235-a382-5b48bf6c3b2f | Kisqali 200 MG Oral Tablet | PSN | 25 | These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI ® FEMARA ® CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral use Initial U.S. Approval: 2017 | 20250916 |